Bartosz Olechowski
Overview
Explore the profile of Bartosz Olechowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
69
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tucker S, Olechowski B, Swallow R
Postgrad Med J
. 2023 Apr;
98(e1):e2-e3.
PMID: 37066548
No abstract available.
2.
Saririan M, Armstrong R, George J, Olechowski B, OConnor S, Byrd J, et al.
Eur Heart J Case Rep
. 2021 Mar;
5(2):ytaa553.
PMID: 33644657
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the now pandemic disease, coronavirus disease (COVID-19). A number of reports have emerged suggesting these patients...
3.
Mahmoudi M, Gormaz J, Erazo M, Howard M, Baeza C, Feelisch M, et al.
Oxid Med Cell Longev
. 2019 Dec;
2019:6217837.
PMID: 31827686
Myocardial ischemia/reperfusion-related oxidative stress as a result of cardiopulmonary bypass is thought to contribute to the adverse clinical outcomes following surgical aortic valve replacement (SAVR). Although the acute response following...
4.
Mariathas M, Allan R, Ramamoorthy S, Olechowski B, Hinton J, Azor M, et al.
BMJ
. 2019 Mar;
364:l729.
PMID: 30867154
Objective: To determine the distribution, and specifically the true 99th centile, of high sensitivity cardiac troponin I (hs-cTnI) for a whole hospital population by applying the hs-cTnI assay currently used...
5.
Olechowski B, Dalton R, Khanna V, Ashby A, Vavyla M, Mariathas M, et al.
Cardiovasc Ther
. 2018 Apr;
36(4):e12433.
PMID: 29682911
Introduction: There is potential value in testing individual response to P2Y12 inhibitors to predict ischemic and bleeding risk in patients undergoing percutaneous coronary intervention. The aims of this study were:...
6.
Mariathas M, Gemmell C, Olechowski B, Nicholas Z, Mahmoudi M, Curzen N
Cardiovasc Revasc Med
. 2018 Jan;
19(5 Pt A):487-492.
PMID: 29352700
Background: The introduction of the highly sensitive troponin (hs-trop) assays into clinical practice has allowed for the more rapid diagnosis or exclusion of type 1 myocardial infarctions (T1MI) by clinicians,...
7.
Mariathas M, Olechowski B, Mahmoudi M, Curzen N
Expert Rev Cardiovasc Ther
. 2017 Dec;
16(1):49-57.
PMID: 29260921
Troponin is considered to be the gold standard biomarker for ruling out MI. There has been a drive to improve the diagnostic speed, and as such the high sensitivity cardiac...
8.
Olechowski B, Khanna V, Mariathas M, Ashby A, Dalton R, Nordon I, et al.
Platelets
. 2017 Dec;
30(2):190-198.
PMID: 29227173
The role of platelets in ischaemic events is well established. Aspirin represents the default antiplatelet and blocks the metabolism of arachidonic acid (AA) at the cyclo-oxygenase enzyme (COX). AA is...
9.
Mariathas M, Olechowski B, Mahmoudi M, Curzen N
Expert Rev Cardiovasc Ther
. 2016 Dec;
15(2):75-81.
PMID: 27983887
There remains considerable heterogeneity in the management of significant lesions in non culprit coronary arteries in STEMI patients undergoing primary percutaneous coronary intervention (PPCI). Three recent randomised trials have shown...
10.
Olechowski B, Fitzsimmons S, Thomas S, Richens T, OKane P
Clin Med (Lond)
. 2016 Dec;
16(6):602-603.
PMID: 27927831
No abstract available.